The Web cast will be archived, on both Web sites, for 30 days following the call. About Bio-Reference Laboratories, Inc. The Company is the largest independent regional clinical laboratory in the ...

Although we don't believe intiming the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) executed a Restitution Agreement with John Littleton, a former vice president in sales. Pursuant to the Agreement ...

Independent regional clinical laboratory expects net income in the third quarter to be even with the prior year third quarter and hopes to see an improvement in fourth-quarter results over the prior ...

Bio-Reference Laboratories (NASDAQ: BRLI) reported earnings on June 6. Here are the numbers you need to know. The 10-second takeaway For the quarter ended April 30 (Q2), Bio-Reference Laboratories met ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- CEO Marc Grodman M.D. of Bio-Reference Laboratories, Inc. (BRLI) (NASDAQ – BRLI) was one of the key panelists at a November 17 bi-partisan policy forum in ...

Many investors appear to be quite bearish on Bio-Reference Laboratories Inc ( BRLI), especially if you look at the percentage of the float that is sold short for this stock. Currently, 28.17% of the ...

What: Marc D. Grodman, M.D., President and CEO of Bio-Reference Laboratories, Inc. (BRLI) will preside over the closing bell to celebrate the Company's 20th listing anniversary on NASDAQ. Where: ...

Is Bio-Reference Laboratories Inc (NASDAQ:BRLI) a buy? At the moment, there are dozens of gauges market participants can use to analyze the equity markets. A duo of the most under-the-radar are hedge ...

What: Shares of Bio-Reference Laboratories, a provider of clinical laboratory testing services, slumped as much as 22% after reporting its preliminary fourth-quarter results and fiscal 2014 full-year ...